Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price increase of 86.54%. However, over the past six months, we’ve seen a weaker performance of 52.76%. The price of SLS fallen by 50.39% over the last 30 days. And in the last five days, it has surged by 37.59%.
In terms of market performance, SELLAS Life Sciences Group Inc had a fairly even. The highest value for the stock in the past year was $1.85 on 05/20/25, and the lowest value was recorded at $0.77 on 12/13/24.
52-week price history of SLS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. SELLAS Life Sciences Group Inc’s current trading price is 4.86% away from its 52-week high, while its distance from the 52-week low is 151.30%. The stock’s price range during this period has varied between$0.77 and $1.85. The SELLAS Life Sciences Group Inc’s shares, which operate in the Healthcare, saw a trading volume of around 4.22 million for the day, a figure considerably higher than their average daily volume of 1.52 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
SELLAS Life Sciences Group Inc (SLS) has experienced a quarterly rise of 53.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 193.57M and boasts a workforce of 15 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2510, with a change in price of +1.0309. Similarly, SELLAS Life Sciences Group Inc recorded 2,318,585 in trading volume during the last 100 days, posting a change of +113.40%.
SLS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SLS stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.01.
SLS Stock Stochastic Average
SELLAS Life Sciences Group Inc’s raw stochastic average for the past 50 days is presently 99.00%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 98.48%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 81.26% and 67.66%, respectively.
